These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 15551277

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnessi L.
    Cancer Res; 2005 Mar 01; 65(5):1897-903. PubMed ID: 15753388
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Warren E, Ward S, Gordois A, Scuffham P.
    Clin Ther; 2004 Nov 01; 26(11):1924-33. PubMed ID: 15639704
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Imatinib mesylate responsiveness in aggressive systemic mastocytosis: novel association with a platelet derived growth factor receptor beta mutation.
    Dalal BI, Horsman DE, Bruyèrè H, Forrest DL.
    Am J Hematol; 2007 Jan 01; 82(1):77-9. PubMed ID: 17133421
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.
    Geoerger B, Morland B, Ndiaye A, Doz F, Kalifa G, Geoffray A, Pichon F, Frappaz D, Chatelut E, Opolon P, Hain S, Boderet F, Bosq J, Emile JF, Le Deley MC, Capdeville R, Vassal G, Innovative Therapies for Children with Cancer European Consortium.
    Eur J Cancer; 2009 Sep 01; 45(13):2342-51. PubMed ID: 19362466
    [Abstract] [Full Text] [Related]

  • 31. Response of histiocytoses to imatinib mesylate: fire to ashes.
    Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R.
    J Clin Oncol; 2010 Nov 01; 28(31):e633-6. PubMed ID: 20733125
    [No Abstract] [Full Text] [Related]

  • 32. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon.
    Breccia M, Diverio D, Pane F, Nanni M, Russo E, Biondo F, Frustaci A, Gentilini F, Alimena G.
    Leuk Res; 2006 Dec 01; 30(12):1577-9. PubMed ID: 16630657
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
    Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK.
    Oncology; 2009 Dec 01; 76(5):326-32. PubMed ID: 19307738
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).
    Levine RL, Wadleigh M, Sternberg DW, Wlodarska I, Galinsky I, Stone RM, DeAngelo DJ, Gilliland DG, Cools J.
    Leukemia; 2005 Jan 01; 19(1):27-30. PubMed ID: 15496975
    [Abstract] [Full Text] [Related]

  • 40. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement.
    Arefi M, García JL, Peñarrubia MJ, Queizán JA, Hermosín L, López-Corral L, Megido M, Giraldo P, de las Heras N, Vanegas RJ, Gutiérrez NC, Hernández-Rivas JM.
    Eur J Haematol; 2012 Jul 01; 89(1):37-41. PubMed ID: 22587685
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.